Position in DNLI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$252,960
+$44,753 QoQ
Shares Held
13,175
+4.5% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Perbak Capital Partners LLP holds $5,346,476 across 14 Biotechnology names. DNLI ranks #10 (4.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,205 | $931,031 | |
| 2 | MRNA |
Moderna, Inc.
|
10,991 | $558,342 | |
| 3 | KYMR |
Kymera Therapeutics, Inc.
|
6,443 | $536,637 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
3,058 | $516,863 | |
| 5 | EXEL |
Exelixis, Inc.
|
10,027 | $430,058 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,205 | $398,698 | |
| 7 | CAI |
Caris Life Sciences, Inc.
|
22,001 | $393,377 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
9,709 | $391,369 |
All Filings in DNLI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $252,960 | 13,175 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $208,207 | 12,611 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||